Australia's most trusted
source of pharma news
Posted 3 November 2025 AM
Some pharmas are celebrating their first ARTG listing this week, including an Australian company aiming for an export market.
Hovid has registered its first pharmaceutical product on the ARTG, Celecoxib Hovid for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, primary dysmenorrhoea in adults, and the short-term treatment of acute pain in adults following surgery or musculoskeletal or soft tissue injury. The Malaysian pharma distributes beauty and consumer health products, and achieved TGA-GMP certification in 2022.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.